interleukin-1 γ (il-1 γ)

PCC0208018 is a novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1) programmed cell death-ligand 1 (PD-L1) binding and not directly affecting tumor cell viability in vitro.

Delmitide acetate (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory properties, suppressing TNF-α, IFN-γ, and interleukin (IL)-12 production, while enhancing heme oxygenase 1 activity. It is utilized in research related to ulcerative colitis [1] [2].

QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following interleukin-12 (IL-12) stimulation and markedly improves skin lesions in a psoriatic mouse model [1].